GeoVax Labs (GOVX) Other Non-Current Assets (2010 - 2026)
GeoVax Labs (GOVX) posted quarterly Other Non-Current Assets of $69947.0 for Q2 2026, down 1.5% year-over-year from $71010.0 in Q2 2025, and down 19.55% quarter-over-quarter from $86947.0 in Q4 2025.
GeoVax Labs (GOVX) Other Non-Current Assets (2010 - 2026) Analysis & Trends
GeoVax Labs (GOVX) has reported Other Non-Current Assets for 17 consecutive years, with $69947.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non-Current Assets fell 1.5% year-over-year to $69947.0; the TTM figure through Jun 2026 stood at $69947.0 (down 1.5% YoY), while the FY2025 annual figure was $86947.0, up 22.44% from the prior year.
- Other Non-Current Assets fell to $69947.0 in Q2 2026 per GOVX's latest filing, from $86947.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $2.2 million in Q3 2022 and bottomed at $11010.0 in Q1 2022.
- Historically, Other Non-Current Assets has averaged $649577.9 across 5 years, with a median of $86947.0 in 2025.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 19739.11% — and 2024, when it slumped 94.02%.
- GeoVax Labs' Other Non-Current Assets stood at $2.2 million in 2022, then plunged by 45.37% to $1.2 million in 2023, then plunged by 94.02% to $71010.0 in 2024, then climbed by 22.44% to $86947.0 in 2025, then declined by 19.55% to $69947.0 in 2026.
- Business Quant data shows GOVX's Other Non-Current Assets at $69947.0 in Q2 2026, $86947.0 in Q4 2025, and $86947.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | GeoVax Labs | 2.88 Mn | -260,493.75 | - | 69,947.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 69,947.00 |
| Dec 31, 2025 | 86,947.00 |
| Sep 30, 2025 | 86,947.00 |
| Jun 30, 2025 | 71,010.00 |
| Mar 31, 2025 | 71,010.00 |
| Dec 31, 2024 | 71,010.00 |
| Sep 30, 2024 | 71,010.00 |
| Jun 30, 2024 | 81,010.00 |
| Mar 31, 2024 | 305,691.00 |
| Dec 31, 2023 | 1.19 Mn |
| Sep 30, 2023 | 1.19 Mn |
| Jun 30, 2023 | 1.20 Mn |
| Mar 31, 2023 | 1.20 Mn |
| Dec 31, 2022 | 2.17 Mn |
| Sep 30, 2022 | 2.18 Mn |
| Jun 30, 2022 | 987,508.00 |
| Mar 31, 2022 | 11,010.00 |
| Dec 31, 2021 | 11,010.00 |
| Sep 30, 2021 | 11,010.00 |
| Jun 30, 2021 | 11,010.00 |